U.S. Markets closed

Pharmacyclics

Pharmacyclics (PCYC) said the FDA accepted its supplemental new drug application for full approval of Imbruvica for the treatment of B-cell chronic lymphocytic leukemia in patients who have received at least one prior therapy. Shares rose 3.8% to 97.07.